Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies

被引：0
|
作者：
Vermersch, P. [1 ]
Comi, G. [2 ]
Siva, A. [3 ]
Oreja-Guevara, C. [4 ]
Wiendl, H. [5 ]
Van Wijmeersch, B. [6 ]
Eralinna, J. -P. [7 ]
Nicholas, R. [8 ]
Buffels, R. [9 ]
Bernasconi, C. [9 ]
Kuhelj, R. [9 ]
机构：
[1] Univ Lille, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Istanbul Univ, Istanbul, Turkey
[4] Univ Hosp San Carlos, Madrid, Spain
[5] Univ Munster, Munster, Germany
[6] Univ Hasselt, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium
[7] Univ Turku, Turku, Finland
[8] Imperial Coll London, London, England
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO2077
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [1] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [2] Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
    Weinstock-Guttman, Bianca
    Bermel, Robert
    Cutter, Gary
    Freedman, Mark S.
    Leist, Thomas P.
    Ma, Xiaoye
    Kile, Deidre
    Musch, Bruno
    Reder, Anthony T.
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 790 - 800
  • [3] Pregnancy and disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Oztekin, N. S.
    Oztekin, M. F.
    MULTIPLE SCLEROSIS, 2006, 12 : S95 - S96
  • [4] Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment
    Bermel, R.
    Comi, G.
    Eralinna, J. -P.
    Leist, T. P.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Bernasconi, C.
    Buffels, R.
    Csoboth, C.
    Han, J.
    Musch, B.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 615 - 616
  • [5] Two-year results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy
    Weinstock-Guttman, Bianca
    Bermel, Robert
    Csoboth, Csilla
    Cutter, Gary
    Freedman, Mark
    Leist, Thomas
    Ma, Xiaoye
    Musch, Bruno
    Reder, Anthony
    Stankiewicz, James
    Wolinsky, Jerry
    NEUROLOGY, 2020, 94 (15)
  • [6] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [7] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
    Vermersch, P.
    Eralinna, J. -P.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Kuhelj, R.
    Wei, W.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 344 - 345
  • [8] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
    Vermersch, P.
    Eralinna, J. P.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Kuhelj, R.
    Wei, W.
    Comi, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [9] One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments
    Leist, Thomas
    Reder, Anthony
    Bermel, Robert
    Weinstock-Guttman, Bianca
    Freedman, Mark
    Cutter, Gary
    Stankiewicz, James
    Ma, Xiaoye
    Musch, Bruno
    Csoboth, Csilla
    Wolinsky, Jerry
    NEUROLOGY, 2019, 92 (15)
  • [10] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
12345